Structure Therapeutics reports Phase 1/2a data showing 3.3% weight loss for oral amylin agonist ACCG-2671

• Structure Therapeutics reported positive early-stage results for ACCG-2671, an oral amylin-based candidate for chronic weight management.
• Findings have already been presented from a single-dose study, showing signs of weight reduction with a tolerable safety profile.
• A longer multiple-dose trial in people with obesity is underway, with results scheduled for 1H 2027.
• Separate longer-term study results have already been presented for oral GLP-1 candidate aleniglipron, supporting durable weight loss with improved tolerability.
• Two registrational Phase 3 trials for aleniglipron are enrolling, with topline results expected in 2H 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080800PRIMZONEFULLFEED9822578) on September 08, 2026, and is solely responsible for the information contained therein.